Roche makes hostile takeover bid for life sciences group Illumina
Swiss drug giant Roche Holding on Wednesday made a hostile $5.7bn bid for DNA diagnostics company Illumina. Roche had previously attempted “multiple efforts” to start negotiations but Illumina refused to enter into “substantive discussion,” the company said. The offering of $44.50 a share represents an 18 percent premium over Illumina’s closing price per share on…